LabGenius: Using synthetic biology, machine learning and robotics to discover a safer, more effective Nectin-4 T-cell engager for advanced cancers.

LabGenius是一家英国生物技术公司，结合了机器人自动化、合成生物学和先进的机器学习，探索蛋白质适应性并同时改善多种药物特性。LabGenius的使命是通过率先开发智能机器人平台（** 伊娃（tm）**）来加速下一代治疗性抗体的发现，该平台能够设计、执行并从自己的实验中学习。癌症是全球头号死因，超过40%的男性和女性在其一生中被诊断出患有癌症（John霍普金斯，2022）。2021年癌症的经济成本估计为9300亿英镑，预计这一成本将上升。仅在英国，每年就有35万例新的癌症病例（ONS，2022）。常见癌症包括影响肺部（13%）、膀胱（3%）和卵巢（2%）的癌症（Siegel，2022）。T细胞增殖剂（TCE）被认为是成功治疗癌症而不对身体其他部位产生负面影响的一种方法，然而，迄今为止，只有两种TCE上市，因为许多TCE因严重的副作用和低疗效而在临床试验中失败。在这个项目中，LabGenius将使用他们的机器学习驱动的方法来优化用于治疗晚期癌症的T细胞增殖剂，使疗效和安全性更好的候选人能够得到进一步发展。LabGenius的技术平台使其在发现候选药物的速度和质量方面的竞争中脱颖而出。

LabGenius is a UK biotechnology company that combines robotic automation, synthetic biology and advanced machine learning to explore protein fitness landscapes and improve multiple drug properties simultaneously. LabGenius' mission is to accelerate the discovery of next-generation therapeutic antibodies by pioneering the development of a smart robotic platform (**EVA(tm)**) that is capable of designing, conducting and, critically, learning from its own experiments.Cancer is the number one cause of death worldwide with over 40% of men and women being diagnosed with cancer in their lifetime (John Hopkins, 2022). The economic cost of cancer was estimated at £930 billion in 2021 and this cost is expected to rise. In the UK alone there are \>350,000 new cases of cancer a year (ONS,2022). Common cancers include those affecting the lungs (13%), bladder (3%) and ovaries (2%) (Siegel,2022). T-cell engagers (TCE) are seen as a way forward to treat cancers successfully without negatively impacting the rest of the body, however, to date only two TCEs have been marketed as many fail in clinical trials due to severe adverse side effects and low efficacy.In this project, LabGenius will use their machine learning-driven approach to optimise a T-cell engager for the treatment of advanced cancers, enabling candidates with better efficacy and safety to be taken forward for future development. LabGenius' technology platform sets it apart from the competition in speed and quality of drug candidates discovered.